Improving the care of high-risk patients: the potential of PCSK9.
Kronhusgatan 11, 411 05 Gothenburg, Sweden. Electronic address: office@eas-society.org.
Jane
J
Stock
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy* / Q000517:prevention & control; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D006801:Humans; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*; D034741:RNA, Small Interfering / Q000378:metabolism / Q000627:therapeutic use; D012306:Risk; D012697:Serine Endopeptidases
C585830:ALN-PCS; D000911:Antibodies, Monoclonal; D008078:Cholesterol, LDL; D034741:RNA, Small Interfering; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases